Navigation Links
Urocidin™ Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.
Date:5/17/2011

CHADDS FORD, Pa. and BELLEVILLE, Ontario, May 17, 2011 /PRNewswire/ -- Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C. The preliminary results from the interim analysis of this prospective trial indicate that Urocidin™ may provide an alternative to cystectomy for patients with bacillus Calmette-Guerin (BCG) refractory non-muscle invasive bladder cancer (NMIBC).

The preliminary results were generated from an interim analysis in an ongoing Phase III trial with Urocidin™ in the treatment of NMIBC that is refractory to BCG and at high risk of progression.

The Results

A total of 129 patients were enrolled from 25 centers in the U.S. and Canada, with high grade papillary tumors and/or carcinoma in situ (CIS) and having failed to respond to one or more courses of BCG. According to the preliminary results the overall one-year disease-free survival (DFS) rate was 25 percent. DFS is defined as lack of recurrence or progression to muscle-invasive disease, as confirmed by biopsy. The one-year DFS rate was 35 percent for patients with only papillary tumors and 21 percent for patients with carcinoma in situ (CIS) with or without papillary tumors. The preliminary results indicate that intravesical administration of Urocidin™ was well tolerated.

Ongoing Phase III Clinical Program with Urocidin™

Summary details of a Phase III clinical trial protocol with Urocidin™ being conducted by Endo are publicly available via the U.S. National Institutes of Health (NIH) clinical trial registration service at http://www.clinicaltrials.gov. This trial is active
'/>"/>

SOURCE Endo Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Urocidin™ Phase III Clinical Trial Results to be Presented at EAU and AUA Conferences
2. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
3. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
4. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
5. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
6. Independent Investigator Initiates Phase 1 Study of Biodels Ultra-Rapid-Acting Insulin Formulations in Patients Using Insulin Pumps
7. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
8. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
9. Selexys Pharmaceuticals Initiates Enrollment in Phase I Clinical Study of SelG1
10. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
11. Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... ... ... - Spasticity Affects a Significant Number of Post-Stroke ... , , ...
... Robbins & Myers, Inc. (NYSE: RBN ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of ...
Cached Medicine Technology:First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 2First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 3First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 4First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 5First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 6First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 7First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 8First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity 9
(Date:8/21/2014)... 21, 2014 Lauren Collura, a mother of ... “Back to the Boardwalk” Facebook sweepstakes. Lauren, her husband, and ... four-bedroom beachfront house in Lavallette beginning this Saturday. , ... Boardwalk” sweepstakes. Last year, Horizon Blue Cross Blue Shield of ... Superstorm Sandy and decided to make it a new summer ...
(Date:8/21/2014)... 21, 2014 American Addiction Centers, a ... for individuals with drug and/or alcohol addiction, has been ... Growing Private Companies. , The company is ranked 7th ... list and 4th on the list in the “Nashville ... of 995%, American Addiction Centers (AAC) ascended to number ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Using two types ... the disease and may boost efforts to eradicate polio, ... 1,000 children in India found that giving the Salk ... been given the Sabin live-attenuated oral poliovirus vaccine (OPV) ... causes polio. The findings, reported in the Aug. ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pleio, ... adherence, is launching a new suite of services ... offerings assist retail pharmacy by applying proven behavior ... classes, resulting in increased medication adherence, higher PDC ... As such, Pleio’s PDC-targeted offerings align retail’s desire ...
(Date:8/21/2014)... developed a way to use a laser to measure ... the laser system to a portable size, the technique ... themselves to draw blood. , "We are working hard ... to use in their daily lives," said Claire Gmachl, ... project,s senior researcher. "With this work we hope to ...
Breaking Medicine News(10 mins):Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 3
... obese men because the telltale blood marker used to detect ... population, according to a new study led by Duke Prostate ... their bodies than normal weight men, and as a result, ... -- the gold standard for detecting prostate cancer -- can ...
... The extra blood volume produced in the obese may so ... the popular PSA test may be essentially useless for diagnosing ... in The Journal of the American Medical Association suggests. ... 13,000 prostate cancer patients at The Johns Hopkins Hospital and ...
... first reliable follow-up for patients after treatment, researchers ... Whole-body positron emission tomography (PET) scans three months ... help determine whether they,re cancer-free or require further ... difficult to determine if treatment has eliminated cervical ...
... survival of very sick children, study finds , , TUESDAY, ... team of experts at a children,s hospital can cut ... outside the intensive care unit, a new study suggests. ... improvement in mortality, so that adds to the potential ...
... offers formulas of essential prenatal ... ... Mission Pharmacal today announced,the launch of the CitraNatal(TM) family of ... of essential vitamins,and minerals for women prior to conception, throughout ...
... Kelle Ilitch, an,entrepreneur trained in Pilates, is bringing the ... boutique, Pure Element Pilates.,Ilitch,s version of the innovative barre ... weights, Pilates and dance exercises,in rapid sequence to tone ... available at any other studios in the area. ...
Cached Medicine News:Health News:Study suggests adjusting PSA scores for obese men or cancers may be missed 2Health News:Obesity-linked high blood volumes render PSA prostate cancer test less effective, study suggests 2Health News:PET Scans Can Spot Cervical Cancer's Return 2Health News:Rapid Response Teams Can Save Hospitalized Kids 2Health News:Rapid Response Teams Can Save Hospitalized Kids 3Health News:Mission Pharmacal Launches CitraNatal(TM) Prescription Prenatal Vitamin Line 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 2Health News:Ilitch Brings New Brand of Pilates to Metro Detroit With Opening of Studio in West Bloomfield 3
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alkaline Phosphatase in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: